This content is only available for ASCRS Members
This content from the 2020 ASCRS Virtual Annual Meeting is only available to ASCRS members. To log in, click the teal "Login" button in the upper right-hand corner of this page.
Filed Under
Refractive
Astigmatism
phakic IOL
implantable collamer lens
Visian ICL
refractive outcomes
myopia
2020 paper presentation
Purpose
To evaluate the predictability, stability, safety, and efficacy of the Toric V4c Visian Implantable Collamer Lens (ICL) with central hole to correct moderate to high astigmatism.
Methods
Sixty five (65) eyes of 40 patients were evaluated after implantation of the toric V4c ICL. The refraction, best corrected visual acuity (BCVA), uncorrected visual acuity (UCVA), vault, and adverse effects were evaluated throughout 12-months.
Results
The mean spherical equivalent dropped from -6.30 ± 3.79 D (Diopters) preoperatively to -0.15 ± 0.32 D postoperatively, with 90.8% eyes being within ±0.50 D of the desired refraction. The mean refractive cylinder components dropped from J0 = 0.67 ± 0.82 D to J0 = 0.06 ± 0.13 D, and J45 = 0.12 ± 0.65 D to J45 = -0.01 ± 0.15 D. At 12-months, the mean logMAR BCVA was -0.03 ± 0.04, the mean logMAR UCVA was -0.03 ± 0.04, and 36.9 % of eyes gained 1 or more lines of BCVA. Safety and efficacy indexes (with decimal visual acuities) were 1.07 and 1.06, respectively. No intraoperative complications were reported. Two ICLs required an exchange because their length were too short.
Conclusion
The visual and refractive outcomes were very good and highly stable throughout the follow-up period, showing that this toric ICL model may be predictable, stable, safe, and effective to correct moderate to high astigmatism.
To evaluate the predictability, stability, safety, and efficacy of the Toric V4c Visian Implantable Collamer Lens (ICL) with central hole to correct moderate to high astigmatism.
Methods
Sixty five (65) eyes of 40 patients were evaluated after implantation of the toric V4c ICL. The refraction, best corrected visual acuity (BCVA), uncorrected visual acuity (UCVA), vault, and adverse effects were evaluated throughout 12-months.
Results
The mean spherical equivalent dropped from -6.30 ± 3.79 D (Diopters) preoperatively to -0.15 ± 0.32 D postoperatively, with 90.8% eyes being within ±0.50 D of the desired refraction. The mean refractive cylinder components dropped from J0 = 0.67 ± 0.82 D to J0 = 0.06 ± 0.13 D, and J45 = 0.12 ± 0.65 D to J45 = -0.01 ± 0.15 D. At 12-months, the mean logMAR BCVA was -0.03 ± 0.04, the mean logMAR UCVA was -0.03 ± 0.04, and 36.9 % of eyes gained 1 or more lines of BCVA. Safety and efficacy indexes (with decimal visual acuities) were 1.07 and 1.06, respectively. No intraoperative complications were reported. Two ICLs required an exchange because their length were too short.
Conclusion
The visual and refractive outcomes were very good and highly stable throughout the follow-up period, showing that this toric ICL model may be predictable, stable, safe, and effective to correct moderate to high astigmatism.
View More Presentations from this Session
This presentation is from the session "SPS-104 Refractive Procedure Outcomes: SMILE, SMILE & CXL, ICL" from the 2020 ASCRS Virtual Annual Meeting held on May 16-17, 2020.